Contribution from Final International University
The U.S. Food and Drug Administration (FDA) has approved a new drug called Kerendia, seen as a new hope in the treatment of heart failure. Prof. Dr. İbrahim Benter stated that this development marks a major turning point in translating scientific research into clinical success.

On July 14, 2025, the FDA announced that following successful results from clinical trials in humans, Kerendia has been approved as an additional option to existing heart failure treatments.

Heart conditions affect millions of people worldwide, and the inadequacy of current medications is driving a growing need for new treatment options. Kerendia, approved by the FDA, belongs to the class of mineralocorticoid receptor antagonists and holds the distinction of being the first drug in this category approved for heart failure treatment.

Prof. Dr. İbrahim Benter, Dean of the Faculty of Pharmacy at Final International University, emphasized that this development represents a major milestone for the scientific community. He recalled that in a 2013 scientific study, they demonstrated that drugs similar to Kerendia could be effective in treating heart conditions both in healthy individuals and in diabetic patients.

In his statement, Prof. Dr. Benter said: “We showed that this class of drugs could provide positive effects on heart health, especially in diabetic patients. Therefore, continuing research with molecules like Kerendia in this patient group is of great importance.”